glp 1 t vs glp 1 s GLP-1 Agonists - What is it? Is GLP-1 the Same as

Why Blood Sugar May Not Be Very High In classic DKA: Insulin deficiency severe hyperglycemia In euglycemic DKA: Some insulin is still being administered Blood glucose may appear only mildly elevated But insulin is insufficient to prevent ketogenesis This can delay recognition because: Patients and clinicians may not suspect DKA with glucose under 250 mg/dL Symptoms may initially resemble dehydration or GI illness Additional Contributing Factors GLP-1 use in Type 1 diabetes may also increase DKA risk due to: Vomiting dehydration stress hormones ketone rise Intentional insulin reduction due to fear of hypoglycemia Reduced basal insulin during weight loss Increased glycemic variability from delayed gastric emptying Hypoglycemia and the Insulin Reduction Trap Another issue is the cycle that can develop: Appetite decreases Insulin dose is reduced Hypoglycemia occurs intermittently Insulin is reduced further Ketone production increases Over time, this can push the patient into metabolic instability

Sherwin et al (2023) : Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: a prospective observational study in volunteers without obesity recently started on semaglutide Twenty patients were given semaglutide or a control, with the following results after an 8-hour fasting period: Supine position: 70% of semaglutide participants and 10% of control participants had solids present on gastric ultrasound

Assuming higher participation rates ranging from 50% to 75%, the cost to Medicare would be between $6.7 billion and $10 billion

Eli Lillys orforglipron (Foundayo) was the oral GLP-1 used in recent research showing that it can help to maintain weight loss after using an injectable

The microdosing approach Microdosing tirzepatide has gained attention as a strategy for minimizing side effects while still achieving therapeutic benefits